The role of Herceptin in early breast cancer

Herceptin is widely regarded as the most important development in the treatment of breast cancer since Tamoxifen and the development of the multidisciplinary team (MDT). It is particularly exciting from an oncological polint of view as it represents success in the emerging field of specific targeted...

Descripción completa

Detalles Bibliográficos
Autores principales: Subramanian, Ashok, Mokbel, Kefah
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2008
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2383915/
https://www.ncbi.nlm.nih.gov/pubmed/18442393
http://dx.doi.org/10.1186/1477-7800-5-9
_version_ 1782154833416945664
author Subramanian, Ashok
Mokbel, Kefah
author_facet Subramanian, Ashok
Mokbel, Kefah
author_sort Subramanian, Ashok
collection PubMed
description Herceptin is widely regarded as the most important development in the treatment of breast cancer since Tamoxifen and the development of the multidisciplinary team (MDT). It is particularly exciting from an oncological polint of view as it represents success in the emerging field of specific targeted therapies to specific molecular abnormalities in tumour cells. This review will focus on the nature of the Her2 overexpression and the role of herceptin in the treatment of early breast cancer.
format Text
id pubmed-2383915
institution National Center for Biotechnology Information
language English
publishDate 2008
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-23839152008-05-14 The role of Herceptin in early breast cancer Subramanian, Ashok Mokbel, Kefah Int Semin Surg Oncol Review Herceptin is widely regarded as the most important development in the treatment of breast cancer since Tamoxifen and the development of the multidisciplinary team (MDT). It is particularly exciting from an oncological polint of view as it represents success in the emerging field of specific targeted therapies to specific molecular abnormalities in tumour cells. This review will focus on the nature of the Her2 overexpression and the role of herceptin in the treatment of early breast cancer. BioMed Central 2008-04-28 /pmc/articles/PMC2383915/ /pubmed/18442393 http://dx.doi.org/10.1186/1477-7800-5-9 Text en Copyright © 2008 Subramanian and Mokbel; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review
Subramanian, Ashok
Mokbel, Kefah
The role of Herceptin in early breast cancer
title The role of Herceptin in early breast cancer
title_full The role of Herceptin in early breast cancer
title_fullStr The role of Herceptin in early breast cancer
title_full_unstemmed The role of Herceptin in early breast cancer
title_short The role of Herceptin in early breast cancer
title_sort role of herceptin in early breast cancer
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2383915/
https://www.ncbi.nlm.nih.gov/pubmed/18442393
http://dx.doi.org/10.1186/1477-7800-5-9
work_keys_str_mv AT subramanianashok theroleofherceptininearlybreastcancer
AT mokbelkefah theroleofherceptininearlybreastcancer
AT subramanianashok roleofherceptininearlybreastcancer
AT mokbelkefah roleofherceptininearlybreastcancer

Ejemplares similares